SOF/VEL

Phase 3Small molecule

Gilead

SOF/VEL is one of 159 small molecule programs targeting Liver Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

158

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Chronic HepatitisActive, not recruiting

Chronic Hepatitis C Virus InfectionActive, not recruiting

CirrhosisActive, not recruiting

Hepatitis C Virus InfectionActive, not recruiting

Liver TransplantPhase 2

Active, not recruiting

Chronic HepatitisPreclinical

Active, not recruiting

Chronic Hepatitis C Virus InfectionPhase 2

Active, not recruiting

CirrhosisPhase 3

Active, not recruiting

Hepatitis C Virus InfectionPhase 3

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

SOF/VEL

Gilead

Phase 3

4 2

PEG-Intron

Merck & Co.

Preclinical

43 3

Sovaldi

Gilead

Preclinical

34 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Roferon-a

Roche

Preclinical

3 7

Medrol

Pfizer

Preclinical

1 8

Dasabuvir

AbbVie

Preclinical

7 9

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

1 10

Interferon Alfa

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cirrhosis6 trials

Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis

Completed· Gilead logo

Gilead·Phase 3·NCT02996682·102 enrolled

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis

Completed· Gilead logo

Gilead·Phase 2·NCT02781558·204 enrolled

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis

Completed· Gilead logo

Gilead·Phase 3·NCT02201901·268 enrolled

Show 3 more trials

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis

Completed· Gilead logo

Gilead·Phase 3·NCT04112303·37 enrolled

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis

Completed· Gilead logo

Gilead·Phase 3·NCT02639338·220 enrolled

Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

Completed· Gilead logo

Gilead·Phase 2·NCT02994056·32 enrolled

Safety and Efficacy5 trials

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

Completed· Gilead logo

Gilead·Phase 2·NCT02378961·128 enrolled

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

Completed· Gilead logo

Gilead·Phase 2·NCT02378935·205 enrolled

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

Completed· Gilead logo

Gilead·Phase 3·NCT02639247·333 enrolled

Show 2 more trials

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy

Completed· Gilead logo

Gilead·Phase 3·NCT02607800·943 enrolled

Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection

Completed· Gilead logo

Gilead·Phase 2·NCT03022981·216 enrolled

Chronic Hepatitis4 trials

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Completed· Gilead logo

Gilead·Phase 3·NCT03074331·130 enrolled

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Terminated· Gilead logo

Gilead··NCT02292706·1,609 enrolled

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Completed· Gilead logo

Gilead·Phase 3·NCT04211909·87 enrolled

Show 1 more trial

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Completed· Gilead logo

Gilead·Phase 3·NCT02480712·107 enrolled

HCV Infection4 trials

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection

Completed· Gilead logo

Gilead·Phase 3·NCT02346721·111 enrolled

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

Completed· Gilead logo

Gilead·Phase 3·NCT02201940·741 enrolled

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection

Completed· Gilead logo

Gilead·Phase 3·NCT02220998·269 enrolled

Show 1 more trial

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

Completed· Gilead logo

Gilead·Phase 3·NCT02201953·558 enrolled

Chronic Hepatitis C Virus Infection4 trials

Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

Completed· Gilead logo

Gilead·Phase 2·NCT02781571·79 enrolled

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

Completed· Gilead logo

Gilead·Phase 3·NCT02722837·119 enrolled

Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease

Completed· Gilead logo

Gilead·Phase 2·NCT03036852·59 enrolled

Show 1 more trial

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Completed· Gilead logo

Gilead·Phase 1·NCT02185794·101 enrolled

4 more indications

Efficacy and Safety3 trials

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection

Completed· Gilead logo

Gilead·Phase 2·NCT02202980·273 enrolled

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV

Completed· Gilead logo

Gilead·Phase 3·NCT02671500·375 enrolled

Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study

Completed· Gilead logo

Gilead·Phase 2·NCT02300103·69 enrolled

Liver Transplant1 trial

Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

Completed· Gilead logo

Gilead·Phase 2·NCT02728206·9 enrolled

Hepatitis C Virus Infection1 trial

Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

Completed· Gilead logo

Gilead·Phase 3·NCT02822794·117 enrolled

LPA1 trial

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

Completed·CCocrystal Pharma, Inc.·Phase 2·NCT03501550·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 29 trial records for SOF/VEL. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SOF/VEL compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SOF/VEL. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Gilead

SOF/VEL

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cirrhosis6 trials

Safety and Efficacy5 trials

Chronic Hepatitis4 trials

HCV Infection4 trials

Chronic Hepatitis C Virus Infection4 trials

Efficacy and Safety3 trials

Liver Transplant1 trial

Hepatitis C Virus Infection1 trial

LPA1 trial

References

Drug Info

Quick Facts

Related News